| Identification | Back Directory | [Name]
Acetamide, N-[2-[[4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]-1,3,5-triazin-2-yl]amino]ethyl]- | [CAS]
2767424-13-3 | [Synonyms]
Acetamide, N-[2-[[4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]-1,3,5-triazin-2-yl]amino]ethyl]- | [Molecular Formula]
C21H23N5O2 | [MOL File]
2767424-13-3.mol | [Molecular Weight]
377.44 |
| Hazard Information | Back Directory | [Uses]
PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells[1]. | [References]
[1] Russomanno P, et al. Interfering with the Tumor-Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors. J Med Chem. 2021;64(21):16020-16045. DOI:10.1021/acs.jmedchem.1c01409 |
|
|